Pulmonx (LUNG) Total Non-Current Liabilities (2019 - 2025)

Pulmonx (LUNG) reported Total Non-Current Liabilities of $75.2 million for Q4 2025, up 94.15% quarter-over-quarter from $38.7 million in Q3 2022.

Pulmonx (LUNG) Total Non-Current Liabilities (2019 - 2025) Analysis & Trends

Pulmonx (LUNG) has 5 years of Total Non-Current Liabilities data on file, last reported at $75.2 million in Q4 2025.

  • Total Non-Current Liabilities for Q4 2025 came in at $75.2 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $75.2 million (changed N/A YoY), and the FY2025 annual result was $75.2 million, changed N/A from the prior year.
  • Total Non-Current Liabilities climbed to $75.2 million in Q4 2025 per LUNG's latest filing, from $38.7 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $75.2 million in Q4 2025 and troughed at $38.7 million in Q3 2022.
  • A 3-year average of $47.3 million and a median of $40.5 million in 2022 frame the typical range for Total Non-Current Liabilities.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Abbott Laboratories 154.42 Bn 147.76 Bn 6.27 Bn -
2 Stryker 118.12 Bn 115.25 Bn 3.81 Bn 20.94 Bn
3 Medtronic 101.72 Bn 93.55 Bn 5.76 Bn 40.52 Bn
4 Boston Scientific 67.19 Bn 65.98 Bn 3.61 Bn 15.78 Bn
5 Edwards Lifesciences 50.69 Bn 47.02 Bn 1.29 Bn 2.44 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 9.85 Bn
7 Dexcom 28.09 Bn 26.97 Bn 750.30 Mn 3.53 Bn
8 GE HealthCare Technologies 28.08 Bn 26.02 Bn 1.98 Bn 24.21 Bn
9 Steris 19.80 Bn 19.37 Bn 697.10 Mn 3.47 Bn
10 Pulmonx 54.38 Mn -15.37 Mn - 75.18 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 75.18 Mn
Sep 30, 2022 38.72 Mn
Jun 30, 2022 40.37 Mn
Mar 31, 2022 40.53 Mn
Dec 31, 2021 41.76 Mn
Sep 30, 2020 68.63 Mn
Dec 31, 2019 34.41 Mn